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A B S T R A C T
Participation in external quality assessment is an integral part of laboratory work and mandatory when the results
have a clinical application, which is one of the requirements of standard 15189 for accreditation of medical laboratories.
Institute of Clinical Chemistry, the first laboratory accredited for clinical cell analysis by flow cytometry in Croatia, par-
ticipated in UKNEQAS for Leukocyte Immunophenotyping in 3 schemes: »Immune Monitoring«, »CD34 Stem Cell Enu-
meration« and »Leukaemia Immunophenotyping«. For sample processing on EPICS XL flow cytometer, lyse/no wash
preparation technique with ammonium chloride (NH4Cl) or ImmunoPrep lysing reagent was employed. In »Immune
monitoring« programme CD45/sideward light scatter (SSC) proposed gating strategy was adopted for lymphocyte sub-
sets, while modified ISHAGE protocol was used for CD34+ cell enumeration. Absolute count determination was per-
formed on flow cytometer using FlowCount beads solution. In the period from the beginning of 2006 until the middle of
2009 a total number of 100 stabilized whole blood samples were processed. The relative and absolute enumeration results
for lymphocyte subsets were within tolerable limits, in 97.1 and 97.1% of cases, and 95 and 90% of CD34+ cell enumera-
tion, respectively. In immune monitoring CD45/SSC proposed gating strategy is the most frequent analysis used (>85%
participants) and ISHAGE protocol for CD34+ cell determination with continuous rise from 76 to 83%. A number of
participants who accept beads method for absolute count enumeration on flow cytometer get greater, 69 to 86%, while
FlowCount was the second of bead-based techniques used (25 and 35%). Sample treatment in lyse/no wash technique us-
ing NH4Cl lysing solution was dominant procedure used by more than 1/3 participants, although its home made solution
has replaced slowly by commercial reagents. The unacceptable results, 6 of 244, were obtained for 20 most frequently de-
termined cell antigens in »Leukaemia Immunophenotyping« samples screened for leukaemia/lymphoma. Processing re-
sults of all participants showed that the deviation from laboratory guidelines and the use of older methods for cell identi-
fication, quantification of cell counting on haematology analyser, or usage an antibody conjugated with fluorochrome
lesser fluorescence quantum often lead to an unacceptable result, although is noticeable trend to accept new referrals and
protocols to reduce the inter-laboratory differences.
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Introduction
Clinical cell analysis by flow cytometry undergoes the
same process of development, instrument and methods
validation, internal control, external quality assessment
(EQA) as any other laboratory medicine activity. Labora-
tory normization through certification or accreditation,
present in the whole world, has become a reality with
growing trend in Croatia. The previous standard ISO/
IEC 17025 from 1999 is replaced with the present one
ISO 15189 in 2003 and the majority of medical laborato-
ries have been accredited according to them. They have
entered the European and have become a part of Cro-
atian legal regulations (HRN EN ISO17025 General re-
quirement for competence of testing and calibrated labo-
ratories, HRN ISO EN15189 Medical laboratories –
Particular requirements for quality and competence)1,2.
The Institute of Clinical Chemistry is the first medical
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laboratory in Croatia accredited for the field of cell im-
munophenotyping, for absolute cell count tests: CD3+
T-lymphocytes, CD4+ T-lymphocytes, CD8+ T-lympho-
cytes, B-lymphocytes, NK cells, Leukocytes (CD45), Stem
Cells (CD34), and relative cell count tests: CD2+, CD3+,
CD4+, CD5+, CD7+,CD8+, CD13+, CD14+, CD19+,
CD33+, CD34+, HLA D/DR+, KAPPA light chain+
B-lymphocytes, LAMBDA light chain+B-lymphocytes.
EQA is objective and necessary factor that compares and
evaluates laboratory test results with the goal of assur-
ing credibility of all laboratory performance aspects:
sampling, analyzing and reporting, when the test results
are included in clinical decision making3–7. In the norm
15189, there is also a requirement included in Article
5.6.4 »Assuring quality of examination procedures« that
conditions participation of laboratory in international
comparisons. One of today’s existing internationally or-
ganized EQA is United Kingdom National External
Quality Assessment Service (UKNEQAS) for Leukocyte
Immunophenotyping. It is generally accepted world stan-
dard due to its robust organization and control appara-
tus; various control schemes that comprise different ar-
eas of laboratory activity like leukemia/lymphoma
immunophenotyping, CD34+ stem cells enumeration,
identification and quantification of lymphocyte popula-
tions, detection of minimal residual disease cells, detec-
tion of residual leukocyte count and other activities, but
mostly due to its accreditation by the Clinical Pathology
Accreditation (CPA) what represents a necessity for labo-
ratories which want to be recognized, certified or accred-
ited. UKNEQAS uses stabilized blood samples collected
from different donors, processed and modified (e.g. selec-
tive elimination of cell populations) providing an image
of pathological sample. It is extremely important that
long-term stabilized samples have enabled elimination of
time-, transportation- and storage-dependent factors and
therefore that inter-laboratory differences originate from
the applied procedure/analysis. This paper aims to show
results of participation of the Institute of Clinical Chem-
istry in UKNEQAS for Leukocyte Immunophenotyping
international control in 3 schemes on the area of cell
immunophenotyping: ImmuneMonitoring, CD34+ Stem
Cell Enumeration and Leukaemia Immunophenotyping
with an overview on applied procedures and laboratory
performance guidelines.
Materials and Methods
A total of 100 blood samples has been processed in the
period from the beginning of 2006 until the middle of
2009 in cycles 0601–0903: 42 in scope the scheme »Im-
mune monitoring«, 40 in »CD34+ Stem Cell Enumera-
tion«, and 18 in the scheme »Leukaemia Immunophe-
notyping«. The scheme »Immune monitoring« includes
several lymphocyte parameters: T-lymphocytes (CD3+),
CD4+ (CD3+CD4+)T and CD8+(CD3+CD8+) T-lym-
phocytes, B-lymphocytes (CD19+) and NK cells (CD3-
CD16+CD56+), and the scheme »CD34+ Stem Cell Enu-
meration« only one, CD34+ cells. Positivity results are
expressed as percentage (%) and absolute number
(´106/L). Samples were stained with antibodies anti -CD3,
-CD4, -CD16, -CD56, -CD19, -CD45, Dako, anti-CD19,
-CD3, -CD8, IQP, or anti-CD3, -CD45, -CD4, -CD8, -CD16,
-CD56, -CD19, Beckman-Coulter for lymphocyte mark-
ers, anti-CD45, Dako or Beckman-Coulter, isotopic con-
trol, Dako, anti -CD34, BD Biosciences were used for de-
termination of CD34+ cells. Before acquisition on flow
cytometer samples were treated with ammonium chlo-
ride (NH4Cl) or ImmunoPrep Reagent System (Coulter)
lysing solution in the »lyse/no-wash« procedure. All mea-
sures were made on EPICS XL flow cytometer, Coulter.
For immune status testing CDC recommended multi-
color analysis was adopted8,9 and for CD34+ cells quanti-
fication ISHAGE protocol was used10. The absolute cell
count on flow cytometer (single platform absolute count-
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TABLE 1




Institute results (N) Consensus means (CV)
inside outside average range
X±SD X±2SD >X±2SD X (min–max)
Percentage of lymphocytes (%) 179/210 (85.2%) 25/210 (11.9) 6/210 (2.9%)
T lymphocyte (CD3+) 33 5 4 3.5 2.2–8.7
CD4+ T lymphocyte 38 4 0 6.8 3.0–23.2
CD8+ T l lymphocyte 37 4 1 7.4 5.1–14.9
B lymphocyte (CD19+) 32 10 0 15.5 8.7–28.5
NK cell (CD3-CD16+CD56+) 39 2 1 16.7 9.3–40.4
Absolute number (´106/L) 155/210 (73.8%) 49/210 (23.3%) 6/210 (2.9%)
T lymphocyte (CD3+) 27 13 2 10.7 8.5–15.0
CD4+ T lymphocyte 28 12 2 12.2 8.7–2.2
CD8+ T lymphocyte 35 6 1 13.5 10.8–20.6
B lymphocyte (CD19+) 27 14 1 21.0 12.5–37.5
NK cell (CD3-CD16+CD56+) 38 4 0 21.6 14.0–41.7
ing) is determined by the method with FlowCount beads
reagent, Beckman-Coulter, a suspension of artificial par-
ticles of defined number11–13. The »Leukaemia Immuno-
phenotyping« programme is divided into two parts: ana-
lytical (»Leukaemia Immunophenotyping«) and diagnostic
(»Leukaemia Diagnosis Interpretation«). In the first part
a number of positive cells is required for: 6 standard, 8
recommended and maximal 6 optional cell antigens, ex-
pressed as percentage in relation to the total number of
mononuclear cells. The certain marker is defined as posi-
tive or negative using defined criteria by the British
Committee for Standards in Hematology (BCSH)14. Ap-
plied antibodies were: anti -CD45, -CD2, -CD3, -CD4,
-CD5, -CD7,-CD10, -CD11c, -CD14, -CD19, -CD20, -CD56,
-CD79a,-CD103, -MPO, -HLA DR, -KAPPA, -LAMBDA
(DAKO), anti –CD3, -CD4, -CD7, -CD8, -CD10, -CD19,
–CD23, -CD25, -CD33, -CD34, -CD38, -CD56, -CD79ß,
-CD117, -CD138 (Beckman-Coulter), anti -CD13, -CD33,
-CD34, -CD117, -HLA DR (BD Biosciences), or anti -CD23,
-CD19 and -TdT (IQP). A total of 18 cycles each with one
sample was performed: 8 with final diagnosis of acute
leukemia (7 acute myeloid leukemia, AML and 1 plasma
cell leukemia, PCL), and 10 of lymphoproliferative dis-
ease (6 B-chronic lymphocytic leukemia, B-CLL, 2 B-cell
prolymphocytic leukemia, B-PLL, 1 T-prolymphocytic leu-
kemia, T-PLL and 1 with hairy cell leukemia, HCL). Af-
ter staining the samples were lysed by NH4Cl solution
and the analysis on flow cytometer was done according to
CD45/sideward scatter (SSC) method for cells identi-
fication14. In the part »Leukaemia Diagnosis Interpreta-
tion« diagnosis is made on the basis of case history data,
morphology images, consensus immunophenotype, cyto-
genetics and results of molecular diagnosis.
Results
During the period from the beginning of 2006 until
the middle of 2009 in 21 cycles of the scheme »Immune
monitoring« 42 venous blood samples for assessing num-
bers of lymphocyte subsets expressed as absolute value
and percentage were processed. Organizer’s acceptance
criteria are X±1 SD as optimal value, and X±2 SD as ac-
ceptable. Coefficient of variation (CV) is variable, de-
pendent on consensus results in certain sample. Table 1
shows the results. For markers there were 179 results,
out of 210 possible results (85.2%), expressed as percent-
age which were within optimal values and 6 results were
outside the allowed limits (2.9%). 155 results for absolute
cell count (73.8%) were within target values and 6 were
outside the allowed limits In the scheme »CD34+ Stem
Cell Enumeration« there were 40 determinations of ab-
solute cell count and their portion expressed as percent-
age to all CD45+ cells. Results are presented in Table 2.
The acceptance criterion was median ±25 centile for tar-
get values and the acceptable result had to be within
range median ±40 centile and it varied with every sam-
ple. There were 20 (50%) results for percentage and 22
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TABLE 2
PRESENTATION OF RESULTS RELATED TO ACCEPTABLE LIMITS AND CONCENSUS MEDIAN VARIATION FROM 40 SAMPLES IN
SCHEME »CD34+ STEM CELL ENUMERATION«
CD34+
cell
Institute results (N) Consensus medians (CV)
inside outside average range
median±25 centile median±40 centile >median±40 centile X min-max

















PRESENTATION OF 20 MOST FREQUENTLY DETERMINED CD
ANTIGENS RESULTS RELATED TO ACCEPTABLE LIMITS FROM
















CD2 16/16 0 15 neg/1 pos
CD3 18/18 0 17 neg/1 pos
CD5 18/18 0 11 neg/7 pos
CD7 15/16 1 false neg 12 neg/4 pos
CD10 16/16 0 15 neg/1 pos
CD13 18/18 0 11 neg/7 pos
CD14 9/9 0 8 neg/1 pos
CD19 17/18 1 false pos 8 neg/10 pos
CD20 15/16 1 false neg 7 neg/9 pos
CD23 8/8 0 3 neg/5 pos
CD33 8/8 0 1 neg/7 pos
CD34 8/8 0 1 neg/7 pos
CD38 8/8 0 5 neg/3 pos
CD45 16/16 0 0 neg/16 pos
CD117 7/7 0 3 neg/4 pos
HLA D/DR 16/16 0 3 neg/13 pos
MPO 9/9 0 3 neg/6 pos
TdT 6/6 0 5 neg/1 pos
KAPPA 5/7 2 false neg 0 neg/7 pos
LAMBDA 5/6 1 false pos 2 neg/4 pos
Neg – negative, pos – positive, according to positive/negative cut
off point of 20% in acute leukemias, and 30% in chronic lympho-
proliferative disorders
(55%) for absolute count of CD34+ cells within optimal
values and outside the limits there were 2 (5%) and 4
(10%) results for relative and absolute count, respec-
tively. Table 3 shows results of 20 most frequently deter-
mined antigens in our laboratory in 18 samples in the
scope of the scheme »Leukaemia Immunophenotyping«.
The result acceptance criterion was median ±25 centile,
that is within limits of ±40 centile, under condition that
they are in the consensus positive or negative area,
whereas criteria for positivity/negativity were from 20%
for acute leukemia and 30% for chronic lymphopro-
liferative diseases. That was all conditioned by the orga-
nizer and BCSH13. Out of 244 results for 20 most com-
mon markers, 6 (2.5%) of them were false positive or
negative while the rest was within target and allowed
limits.
Discussion
Requirements from the Chapter 5 »Technical require-
ments« of the norm 15189 Medical laboratories – Partic-
ular requirements for quality and competence placed be-
fore accredited laboratory relate to instruments used in
examination, methods and procedures for analysis, han-
dling the samples – before, during and after the analysis,
internal controls, reporting on obtained test results, evi-
dences of performed actions and EQA5–7,11–14,16–17. EQA
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Fig. 1. Performance scoring system with positive point’s award for each individual values in current and last 6 determinations coupled
with overall statistics from »Immune Monitoring« scheme report. (With kindly permission of UKNEQAS for Leukocyte Immunopheno-
typing.)
assures measurements to be reliable in all phases of labo-
ratory process that includes sampling, testing and re-
porting in case when results of analysis are involved in
clinical decision making. UKNEQAS for Leukocyte Im-
munophenotyping, CPA accredited organizer of EQA on
the field of cell immunophenotyping represents nowa-
days generally accepted standard with diverse schemes
which evaluate independently and objectively different
tests with application for clinical purposes like leuke-
mia/lymphoma immunophenotyping, CD34+ stem cells
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Fig. 2. Performance score with negative point penalty for CD34+ absolute number in current and last 3 samples with consensus results
for each testing parameters given in „CD34+ Stem Cell Enumeration« scheme report. (With kindly permission of UKNEQAS for Leuko-
cyte Immunophenotyping.)
Fig. 3. Performance scoring system with negative point penalty for each individual antigens in current and 3 last samples compared to
overall results from »Leukaemia Immunophenotyping« scheme report. (With kindly permission of UKNEQAS for Leukocyte Immuno-
phenotyping.)
analysis, CD4+ T-cell count and others. Beside result
evaluation, this assessment includes numerical and gra-
phic diagrams, charts and performance scoring with re-
sults from the last 3 cycles. Figures 1, 2 and 3 show exam-
ples from 3 different schemes. There is also a consulta-
tive aspect of this EQA that recommends acceptance of
adequate methods and helps in control of factors that in-
fluence the accuracy and reproducibility of cell identifica-
tion and quantification. Today it is possible to assure sat-
isfying lymphocyte purity and recovery, >90%, by imple-
menting the CD45/SSC gating strategy for cells identifi-
cation proposed by CDC9–10. The method is also recom-
mended by the Working Group for Laboratory Immunol-
ogy that is active in scope of Croatian Chamber of Medi-
cal Biochemists15 and it has been used in laboratory prac-
tice. In the scheme »Immune Monitoring« more than
85% participants apply this method, while at the same
time the number of laboratories using older methods,
forward-scatter (FSC)/sideward-scatter (SSC) and CD45/
CD14 leuko gate, for lymphocyte gating is decreasing
from 11.3 to 0.8%, regardless the increase in participant
number from 350 to 500 in the period from the beginning
of 2006 until the middle of 2009. The second important
information from this scheme is that the number of par-
ticipants which use flow cytometer to determine absolute
cell count by beads11–12 has been continuously increasing
from 69 to 86% (Figure 4). FlowCount beads used in our
measurements for determination of absolute cell count
on flow cytometer is the second used method in line ac-
cording to frequency of use, about 25%. Analysis per-
formed using older methods and generating absolute cell
count from lymphocyte or leukocyte count on hematolog-
ical counter are factors related to frequent result devia-
tion from allowed limits. There was no influence of
lysator type observed to obtained results, ammonium
chloride vs. ImmunoPrep reagents, nor the influence of
diversity of antibody and conjugated fluorochrome man-
ufacturers what indicates that the quality of the reagents
for analyses of well known cell antigens on the market is
uniform, and it depends rather on individual choice
which reagent will be used. Out of total count 85.2% of
our results for relative and 73.8% for absolute cell count
were within optimal values, and outside allowed limits
were 6% and 6% respectively, due to momentary analyzer
technical condition or antibody combination, however
not due to system error. Average CV for relative cell
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Fig. 4. Methods comparisons for absolute number determination by platform and percentage count by gate used in »Immune Moni-
toring« scheme. (With kindly permission of UKNEQAS for Leukocyte Immunophenotyping.)
count is lower than CV for absolute cell count, what is de-
tailed described in Table 1. The lowest CV was calculated
for CD3+ cells (%) and amounted in average 3.5% with
the lowest value of all parameters that was 2.2%. The
highest average CV values for CD3+(%), CD4+(%) and
NK cells(%) were obtained expectedly in samples with
the lowest determined value of 48.21, 2.89 and 4.21 re-
spectively, different than for CD8+(%) and B-lympho-
cytes(%) where the results were within normal area,
25.04 and 10.24, respectively. For absolute cell count the
average CV for all parameters was higher than 10% and
the lowest was for CD3+(abs) 10.7%, followed by
CD4(abs) 12.2%, CD8(abs) 13.5%, B-lymphocytes(abs)
21.0% and for NK cells(abs) 21.6%. The highest CV for
CD4+(abs) and NK cells(abs) was 26.2 and 41.7% respec-
tively and was calculated from the samples with the low-
est cell count (60 for CD4+ and 36´106/L for NK cells).
Introduction of CD34 marker for identification and quan-
tification of stem cells brought the possibility of perform-
ing analysis on flow cytometer, however only ISHAGE
protocol provided procedure standardization and result
reproducibility10. Normally, there is very small number
of CD34+ cells and therefore, the basis of ISHAGE pro-
tocol is to include multiple logical gates to get the purest
possible population by excluding autofluorescence of
cells, non-specific binding of antibodies, platelets aggre-
gates and optical noise of instrument. Modification of
this protocol has enabled getting absolute CD34+ cells
count on flow cytometer what is also recommendation of
the scheme organizer and the Working Group for Labo-
ratory Immunology of the Croatian Chamber of Medical
Biochemists13,15,18–19 and it has been used in laboratory
practice. Since the beginning of 2006 the number of par-
ticipants in the scheme »CD34+Stem Cell Enumeration«
that used ISHAGE protocol has been increased from 76
to 80% and at the same time the number of participants
that apply single platform for absolute cell count has also
significantly increased from 73% to 83%. FlowCount is in
this scheme also the second used method in line accord-
ing to frequency what makes 35%. Analysis not per-
formed under ISHAGE protocol and generating absolute
cell count from leukocyte count on hematological counter
are factors related to frequent result deviation from al-
lowed limits. There was no influence of applied antibod-
ies for CD34 observed, although in our case the antibody
anti CD45, Dako, showed poorer quality in discrimina-
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Fig. 5. Methods comparisons for CD34+ absolute number and/or percentage count determination by platform, gating strategy or prepa-
ration method for current sample in »CD34+ Stem Cell Enumeration« scheme. (With kindly permission of UKNEQAS for Leukocyte
Immunophenotyping.)
tion between leukocytes vs. no-leukocytes and it was re-
placed by Coulter’s. According to the organizer’s opinion,
lysator carries also significant influence on results vari-
ability (Figure 5). Vast majority of participants applies
ammonium chloride or its commercial preparations due
to its minimal influence on leukocytes and fluorescence
intensity, although sometimes homemade solutions give
higher results, what is also observed in our case, and
have been gradually replaced with commercial reagents
with decreasing tendency from 43 to 38%. This is a con-
trol with a very low CVs, average CV for relative was 11.2
and for absolute count was 9.4%, regarding the higher
complicity of the method in comparison with immune
profile cell analysis and enumeration of cells that are
normally present in very small number. The lowest value
was 2.58´106/L (for absolute count) and 0.04% (for rela-
tive count) and the highest values were 110.00´106/L and
2.24%, the average was within range of 10–30´106/L and
0.20–0.50%, respectively (Figure 6). Cell immunophe-
notyping on flow cytometer has become a routine
practice in management and monitoring of patients with
hematological malignancy. Technical progress in the last
years regarding fluidity, laser technology, optics, analog
and digital data transmission, computers, software, fluo-
rochromes and new antibodies has introduced mass ap-
plication of complex multicolor analysis by flow cyto-
metry in diagnosis of leukemia and lymphoma19. Follow-
ing there events, certain groups have developed recom-
mendations about sample processing methods, relevant
antigens, choice of adequate antibodies and panel gener-
ation, analysis and reporting on obtained results4–7,14,
20,21. In 2006 Subdivision for Laboratory Hematology and
Cytology of the National Group for Hematology and
Transfusion (today: Croatian Co-operative Group for He-
matologic Diseases KROHEM) developed a diagnostic al-
gorithm for Non-Hodgkin lymphoma (NHL) and acute
leukemia (AL) with recommendation of diagnostically
valuable marker, and in 2007 the procedure »Standard
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Fig. 6. Graphical interpretation of cumulative performance score for CD34 percentage and absolute number, and leukocytes determined
on hematology analyzer from »CD34+ Stem Cell Enumeration« scheme. (With kindly permission of UKNEQAS for Leukocyte Immuno-
phenotyping.)
Approach to Diagnosis and Treatment of Acute Leuke-
mia« was accepted on the national level, where routine
diagnostic methods were defined, with cell immunophe-
notyping among others. In the scheme »Leukaemia Im-
munophenotyping« where it is required to identify 20
different cellular markers in every sample, regardless of
the fact that in samples there is dominant blast cell pop-
ulation, the main requirement to fulfil is to conduct
CD45/side-scatter (SSC) analysis. The number of anti-
gens to determine in each sample is higher than 30 be-
tween each cycle what implies that participants use dif-
ferent recommendations or wide panels, regardless of the
assumed diagnosis. There were no differences in results
that would depend on instrument manufacturers: BD
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Fig. 7. Graphical interpretation of cumulative performance score for 2 cell antigens in 3 different cases: 2 positive and 1
negative. Myeloperox – myeloperoxidase, HLADR – HLA D/DR. (With kindly permission of UKNEQAS for Leukocyte
Immunophenotyping.)
Biosciences, Beckman Coulter and Dako. Those differ-
ences originated from applied combinations/panels and
choice of antibody/fluorochrome (Figures 8) and orga-
nizer’s recommendation is (»...This programme has for
many years been highlighting these issues and we urge
participants to carefully select the antibody/fluoro-
chrome. It should be noted that whilst say CD22 FITC
conjugate may work well with normal B-lymphocytes
and provide a good signal to noise separation, the expres-
sion of this antigen, as well as many others, can be highly
variable in cellular development and the leukaemic pro-
cess and thus may not be as highly conserved or as
densely expressed...«) to use antibodies with fluorochro-
me of higher intensity for poorly expressed markers (PE
or PC5 instead FITC). Our test results for markers
which showed deviations outside of consensus acceptable
values: negative CD20 in B-CLL, negative CD7 in AML,
positive CD19 in AML, negative KAPPA and positive
LAMBDA in B-CLL, are also a consequence of insuffi-
ciently clear positive/negative stratification in cases of
antigen’s weak expression in stabilized leukemic control
samples and therefore, they are a consequence of false in-
terpretation of raw measurement data. The problem was
solved by using antibodies from another manufactu-
rer/fluorochrome what was also apparent on results in
following cycles. In the second part »Leukaemia Diagno-
sis Interpretation« which is in pilot phase establishment
of diagnosis is conducted, based on consensus immu-
nophenotype, case history data, digital blood/bone mar-
row smears for morphological analysis, cytogenetics and
molecular genetics data, in case it is performed, by choos-
ing one of offered diagnosis according to the Classifica-
tion of Hematological Malignancies issued by the World
Health Organization (WHO)22. In our case, physicians
were involved in establishing diagnosis: hematologist, cy-
tologist, and medical biochemist. Up to now there have
not been any discrepancies in diagnoses. Educative char-
acter of this part is priceless because the explanation of
definitive, consensus diagnosis includes comments and
conclusions of one or more experts that are made on ba-
sis of relevant data and compared to the definition of
WHO.
Conclusion
EQA is an objective and necessary factor that com-
pares and evaluates laboratory test results with the goal
of credibility improvement of test results and their com-
parability throughout the world. By application of rec-
ommended procedures and protocols in clinical cell anal-
ysis by flow cytometry what includes sample preparation
for measuring and analysis on instrument, it is possible
to assure a high level of inter-laboratory compliance with
complete reliability of obtained test results what is also
apparent in our example.
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VANJSKA PROCJENA KVALITETE U PODRU^JU IMUNOFENOTIPIZACIJE STANICA.
ZA[TO JE TOLIKO VA@NA?
S A @ E T A K
Sudjelovanje u vanjskoj procjeni kvalitete je sastavni dio rada laboratorija za imunofenotipizaciju stanica i neop-
hodan u slu~aju kada rezultati imaju klini~ku primjenu, {to je jedan od zahtjeva va`e}e norme 15189 za akreditaciju
medicinskih laboratorija. Zavod za klini~ku kemiju, prvi akreditirani laboratorij za podru~je imunofenotipizacije sta-
nica u RH, sudjeluje u UKNEQAS for Leukocyte Immunophenotyping kontroli u 3 sheme: »Immune Monitoring«,
»CD34+ stem Cell Enumeration« i »Leukaemia Immunophenotyping«. Za analizu na proto~nom citometru EPICS XL
uzorci su prethodno obra|eni amonij kloridom (NH4Cl) ili ImmunoPrep lizatorom »liziraj/ne ispiri« metodom. U pro-
gramu »Immune Monitoring« CD45/postrani~no raspr{enje (SSC) je kori{teno za analizu limfocita, a modificiran ISHAGE
protokol za brojanje CD34+ stanica. Apsolutni broj je odre|en na citometru s FlowCount beads reagensom. U periodu
od po~etka 2006 do sredine 2009. godine obra|eno je ukupno 100 uzoraka. Od ukupno 210 rezultata relativnog i abso-
lutnog broja limfocitnih stanica upotrebom preporu~ene CDC vi{ebojne analize s CD45/SSC ogra|ivanjem stanica i
FlowCount reagensom za apsolutni broj dobiveni su rezultati bili unutar dozvoljena raspona u 97,1 i 97,1% slu~ajeva,
odnosno u 95 i 90% kod brojanja CD34+ stanica prema ISHAGE protokolu. U »Immune Monitoring« shemi naj~e{}e je
kori{tena CD45/SSC metoda ogra|ivanja (>85% u~esnika), a ISHAGE protokol za odre|ivanje CD34+ stanica sa stal-
nim porastom, 76 na 83%. Istovremeno je porastao i broj u~esnika koji su prihvatili beads-metodu za apsolutni broj
stanica s citometra, 69 na 86%, pri ~emu je FlowCount druga tehnika po u~estalosti (25 i 35%). Priprema uzorka NH4Cl
lizatorom u »liziraj/ne ispiri« tehnici je dominantan postupak i koristi ga vi{e od 1/3 u~esnika, iako se vlastoru~ni
pripravci polako zamjenjuju komercijalnim. U shemi »Leukaemia Immunophenotyping« u 18 uzoraka neprihvatljivi
rezultati su dobiveni u 6 od 244 rezultata za 20 naj~e{}e odre|ivanih stani~nih antigena. Obrada rezultata svih u~es-
nika pokazuje da je odstupanje od laboratorijskih smjernica i kori{tenje starijih metoda identifikacije stanica, kvanti-
fikacija stanica brojanjem na hematolo{kom analizatoru uz kori{tenje protutijela vezanih fluorokromom slabije fluores-
cencije ~esto uzrok neprihvatljivih rezultata.
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